Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Oracle Corporation (ORCL) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Oracle Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Oracle Corporation trades at $148.1 (market cap $423.49B). The key difference: Oracle Corporation is far larger — about 45.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Oracle Corporation pays a 1.36% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOORCL
Market Cap
$9.39B$423.49B
Sector
HealthTechnology
52-Week High
$356.25$328.33
52-Week Low
$241.71$114.99
Enterprise Value
$9.14B$552.74B
Dividend Yield
1.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Oracle Corporation

Oracle (ORCL) trades at $145.45, down 1.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 beating expectations of $1.96, and fundamentals show robust revenue growth, reaching $57.4 billion in 2025, and high profitability with a net margin of 25.37%. Recent news highlights Oracle's AI infrastructure growth and a legal investigation into insider conduct.

Oracle's outlook is positive due to AI-driven demand and consistent earnings outperformance, supported by a consensus analyst price target of $253.63. Key risks include high valuation multiples, rising debt levels, and competitive pressures in cloud services. The stock offers growth potential but requires monitoring of execution risks and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.

Read more on ORCL